An Orthopaedic procedure is a highly collaborative exercise between clinical teams, hospital administration, bio-surgery engineers and industry partners.
Joint Operations has been founded to excel in one particular area, linking clinical teams working in UK hospitals with a network of progressive and innovative manufacturers that are advancing the standard of care within two specific areas of surgery; Joint Preservation and Extremities.
As the name suggests, partnership is the heart of Joint Operations.
On one side we are immensely proud to represent our suppliers within the UK and the Republic of Ireland. Each of these partners has developed unique technology to help Orthopaedic Surgeons resolve unsolved challenges within our chosen specialities.
On the other side, our experienced Sales and Marketing team work in theatres with clinical teams to support them in giving patients the very best clinical outcomes.
BIOBank is a French Human Origin Bone Bank authorised by the French national safety agency for health products, licensed since 2003. BIOBank grafts come from femoral heads harvested exclusively from living donors during hip arthroplasties.
Geistlich Surgery is a long-standing leader in cartilage regeneration and bone formation.
Established in 1985, LifeLink Tissue Bank is the largest not-for-profit tissue bank in the southeast and one of the largest in the United States. They have placed hundreds of thousands of allografts, instilling hope to transplant recipients and their families.
Orteq has a strong focus on Joint Preservation through regeneration of lost meniscus and cartilage tissue.
Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma (platelet concentrate) from the patient’s own blood, used either alone or in combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.
Trice has pioneered technologies that provide a clinical solution that is optimized for the physician’s office providing more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reducing the overall cost to the healthcare system.